VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Ability to understand and willingness to sign a    │ Ability to understand and willingness to sign a    │     100 │
│ written informed consent document                  │ written informed consent document                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age ≥ 18 years                                     │ Age ≥ 18 years                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Histologic diagnosis of chondrosarcoma, verifiable │ Histologic diagnosis of chondrosarcoma, verifiable │     100 │
│ after enrollment                                   │ after enrollment                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Measurable disease                                 │ Measurable disease                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previously treated or incurable disease without    │ Previously treated or incurable disease without    │     100 │
│ options for standard of care therapy               │ options for standard of care therapy               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ECOG performance status of 0-2                     │ ECOG performance status of 0-2                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For patients of reproductive potential (males and  │ For patients of reproductive potential (males and  │     100 │
│ females), use of reliable means for contraception  │ females), use of reliable means for contraception  │         │
│ (e.g., contraceptive pill, intrauterine device     │ (e.g., contraceptive pill, intrauterine device     │         │
│ \[IUD\], physical barrier) throughout the trial    │ [IUD], physical barrier) throughout the trial and  │         │
│ and for 1 year following their final exposure to   │ for 1 year following their final exposure to study │         │
│ study treatment                                    │ treatment                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systemic therapy or radiotherapy within 4 weeks    │ Systemic therapy or radiotherapy within 4 weeks    │     100 │
│ prior to Day 1                                     │ prior to Day 1                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior therapy with agents targeting the DR5        │ Prior therapy with agents targeting the DR5        │     100 │
│ apoptosis pathway                                  │ apoptosis pathway                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major surgical procedure, open biopsy, or          │ Major surgical procedure, open biopsy, or          │     100 │
│ significant traumatic injury within 4 weeks prior  │ significant traumatic injury within 4 weeks prior  │         │
│ to Day 1, or anticipation of need for major        │ to Day 1, or anticipation of need for major        │         │
│ surgical procedure during the course of the study  │ surgical procedure during the course of the study  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other invasive malignancies within 5 years prior   │ Other invasive malignancies within 5 years prior   │     100 │
│ to Day 1                                           │ to Day 1                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known active brain metastases                      │ Known active brain metastases                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled intercurrent illness, including but   │ Uncontrolled intercurrent illness, including but   │     100 │
│ not limited to ongoing or active infection         │ not limited to ongoing or active infection         │         │
│ requiring parenteral antibiotics at enrollment     │ requiring parenteral antibiotics at enrollment     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant, symptomatic cardiovascular │ Clinically significant, symptomatic cardiovascular │     100 │
│ disease, New York Heart Association (NYHA) Grade   │ disease, New York Heart Association (NYHA) Grade   │         │
│ II or greater congestive heart failure, serious    │ II or greater congestive heart failure, serious    │         │
│ cardiac arrhythmia, Grade II or greater peripheral │ cardiac arrhythmia, Grade II or greater peripheral │         │
│ vascular disease, or history of major heart        │ vascular disease, or history of major heart        │         │
│ surgery within 6 months of Day 1, or any situation │ surgery within 6 months of Day 1, or any situation │         │
│ that would likely limit compliance with study      │ that would likely limit compliance with study      │         │
│ requirements                                       │ requirements                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known to be positive for hepatitis C or hepatitis  │ Known to be positive for hepatitis C or hepatitis  │     100 │
│ B surface antigen                                  │ B surface antigen                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of other disease, metabolic dysfunction,   │ History of other disease, metabolic dysfunction,   │     100 │
│ physical examination finding, or clinical          │ physical examination finding, or clinical          │         │
│ laboratory finding giving reasonable suspicion of  │ laboratory finding giving reasonable suspicion of  │         │
│ a disease or condition that contraindicates use of │ a disease or condition that contraindicates use of │         │
│ an investigational drug or that might affect       │ an investigational drug or that might affect       │         │
│ interpretation of the results of the study or      │ interpretation of the results of the study or      │         │
│ render the patient at high risk for treatment      │ render the patient at high risk for treatment      │         │
│ complications                                      │ complications                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of anticoagulation therapy                     │ Use of anticoagulation therapy                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in clinical trials or undergoing     │ Participation in clinical trials or undergoing     │     100 │
│ other investigational procedures within 30 days    │ other investigational procedures within 30 days    │         │
│ prior to Day 1                                     │ prior to Day 1                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or breast feeding                        │ Pregnancy or breast feeding                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known sensitivity to any of the products           │ Known sensitivity to any of the products           │     100 │
│ administered during the study                      │ administered during the study                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any disorder that compromises the ability of the   │ Any disorder that compromises the ability of the   │     100 │
│ patient to give written informed consent and/or    │ patient to give written informed consent and/or    │         │
│ comply with study procedures                       │ comply with study procedures                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy of \> 3 months                     │ Life expectancy of > 3 months                      │      98 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria   │   Score │
╞═══════════════════════════════════╪═════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age ≥ 18 years  │      47 │
╘═══════════════════════════════════╧═════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 97.6086956521739
OverAll Ratio: 98.30434782608695
